8-K: Clearside Biomedical Announces Positive Phase 2b Results for CLS-AX in Wet AMD, Advancing to Phase 3

Clearside Biomedical's CLS-AX demonstrated positive topline results in a Phase 2b trial for wet AMD, showing stable visual acuity and reduced injection frequency, paving the way for Phase 3 development.

Summary

• Clearside Biomedical announced positive topline results from its ODYSSEY Phase 2b clinical trial for CLS-AX in treating wet AMD.
• The trial met its primary endpoint, demonstrating stable best corrected visual acuity (BCVA) over 36 weeks.
• The study also showed stable central subfield thickness (CST), indicating anatomical control of the disease.
• A significant 67% of participants did not require additional treatment for up to 6 months before mandatory re-dosing.
• The injection frequency was reduced by approximately 84% compared to the 24 weeks prior to the study.
• CLS-AX demonstrated a positive safety profile with no ocular or treatment-related serious adverse events.
• The trial enrolled 60 participants with active wet AMD, randomized 2:1 to CLS-AX or aflibercept.
• The CLS-AX arm received a suprachoroidal injection, while the aflibercept arm received an intravitreal injection.
• The study included a mandatory re-dosing of CLS-AX at week 24.
• The results support the potential for a flexible dosing regimen between 3 to 6 months for CLS-AX.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 2b trial, with strong efficacy and safety data, and a clear path to Phase 3. The potential for reduced injection frequency is a significant advantage. The management commentary is also very positive.

Positives

• CLS-AX demonstrated stable visual acuity and anatomical control in wet AMD patients.
• The treatment showed a significant reduction in injection frequency, potentially reducing treatment burden.
• The safety profile of CLS-AX was positive, with no serious ocular or treatment-related adverse events.
• A large proportion of patients experienced extended periods without needing additional treatment.
• The study included a difficult-to-treat patient population with active disease.
• The suprachoroidal delivery method was well-tolerated.
• The results support a flexible dosing regimen, which could be more convenient for patients.
• The trial provides valuable data for planning the Phase 3 program.

Negatives

• The results are preliminary topline data and subject to change.
• The study included a mandatory re-dosing at week 24, which may not reflect real-world treatment needs.
• The study was conducted with a specific patient population that had active disease despite prior treatments.
• The study was only 36 weeks in duration, so long-term efficacy and safety data is not yet available.
• The study was a Phase 2b trial, so further trials are needed to confirm these results.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's plans to develop and commercialize its product candidates are subject to risks.
• There is a risk of adverse differences between preliminary and final data.
• The timing and ability to obtain regulatory approvals for product candidates is uncertain.
• The clinical utility and market acceptance of the product candidates are not guaranteed.
• The company's ability to expand its pipeline is subject to risk.
• The company's estimates regarding future revenue, expenses, and capital requirements are subject to uncertainty.
• The company's ability to identify additional product candidates with significant commercial potential is not guaranteed.

Future Outlook

Clearside plans to advance CLS-AX into Phase 3 development, with a goal of a flexible wet AMD maintenance dosing regimen between 3 to 6 months. They will continue to analyze the ODYSSEY results and conduct an End-of-Phase 2 meeting with the FDA in early 2025.

Management Comments

• George Lasezkay, PharmD, JD, President and CEO, stated that the results strongly support advancing the CLS-AX wet AMD program into Phase 3 development.
• Victor Chong, M.D., MBA, Chief Medical Officer, highlighted the extended duration and stable vision and anatomic measures in a difficult-to-treat patient population.
• David M. Brown, M.D., Director of Research, Retina Consultants Houston, commented that the data is encouraging and demonstrates that suprachoroidal CLS-AX may have sustained durability beyond currently approved agents.

Industry Context

The announcement is significant as it addresses the need for longer-lasting treatments for wet AMD, a major cause of blindness. Current treatments require frequent injections, which can be burdensome for patients. CLS-AX, with its potential for less frequent dosing, could offer a significant advantage over existing therapies.

Comparison to Industry Standards

• Current standard treatments for wet AMD, such as EYLEA, LUCENTIS and VABYSMO, require frequent intravitreal injections, ranging from 3 to 12 times per year.
• The ODYSSEY trial showed that CLS-AX could potentially reduce the injection frequency to 2 to 4 times per year, offering a significant reduction in treatment burden.
• The trial included patients with active disease despite prior anti-VEGF treatments, a population that is often difficult to treat with existing therapies.
• The use of a suprachoroidal injection is a differentiated approach compared to the standard intravitreal injections used by competitors.
• The trial results are comparable to the efficacy seen in trials of other wet AMD treatments, but with the added benefit of reduced injection frequency.

Stakeholder Impact

• Shareholders: The positive results are likely to be viewed favorably by shareholders, potentially increasing the company's stock value.
• Patients: The potential for a less frequent dosing regimen could significantly improve the quality of life for wet AMD patients.
• Physicians: The new treatment option could provide a more convenient and effective way to manage wet AMD.
• Payors: The reduced treatment burden could lead to lower healthcare costs.

Next Steps

• Continue analysis of ODYSSEY results including expert assessments.
• Conduct End-of-Phase 2 meeting with U.S. FDA in early 2025.
• Design Phase 3 trials to produce data supportive of a label with dosing between 3-6 months.

Key Dates

Keywords

wet AMD, CLS-AX, suprachoroidal, axitinib, Phase 2b, clinical trial, BCVA, injection frequency, retinal disease, SCS Microinjector